Ibogaine is the most promising psychedelic with regards to the treatment of substance use disorders. Despite its widespread use in private clinics and underground settings worldwide, there is a scarcity of randomized controlled trials evaluating its safety and efficacy. This study, which is the first Phase-II study of ibogaine for the treatment of methadone dependence, aims to validate a safe clinical protocol for detoxification purposes. Publicly funded and conducted in collaboration with Hospital Universitari Sant Joan de Reus, promoted by ICEERS, the study evaluates the safety and efficacy of low doses of ibogaine on a weekly basis for six weeks. The results of this study will provide valuable information for further research and the advancement of safe clinical use of ibogaine.